Volume 21 Number 20 21 October 2021 Pages 3821-4032

# Labona Chip Devices and applications at the micro- and nanoscale

Devices and applications at the micro- and nanoscale rsc.li/loc



ISSN 1473-0197



**PAPER** Umut A. Gurkan *et al.* Point-of-care microchip electrophoresis for integrated anemia and hemoglobin variant testing

# Lab on a Chip



View Article Online

# PAPER

( Check for updates

Cite this: Lab Chip, 2021, 21, 3863

Received 28th April 2021, Accepted 17th August 2021

DOI: 10.1039/d1lc00371b

rsc.li/loc

## Introduction

Anemia, characterized by a low blood hemoglobin (Hb) level, is among the world's most common and serious health conditions.<sup>1</sup> Anemia has high prevalence affecting a third of the world's population or about 1.62 billion people with the heaviest morbidity and mortality among women and children living in low-and-middle-income countries.<sup>2,3</sup> In sub-Saharan Africa, the prevalence of anemia among preschool children is extremely high and has been reported to be as high as 91% in West Africa.<sup>4</sup> Anemia can cause severe consequences including impaired cognitive and behavioral development in

# Point-of-care microchip electrophoresis for integrated anemia and hemoglobin variant testing<sup>†</sup>

Ran An,<sup>a</sup> Yuncheng Man, <sup>1</sup><sup>10</sup><sup>a</sup> Shamreen Iram, <sup>1</sup><sup>10</sup><sup>b</sup> Erdem Kucukal,<sup>a</sup> Muhammad Noman Hasan, <sup>1</sup><sup>10</sup><sup>a</sup> Yuning Huang,<sup>a</sup> Utku Goreke,<sup>a</sup> Allison Bode,<sup>a</sup> Ailis Hill, <sup>1</sup><sup>10</sup><sup>a</sup> Kevin Cheng,<sup>a</sup> Zoe Sekyonda,<sup>c</sup> Sanjay P. Ahuja,<sup>d</sup> Jane A. Little,<sup>e</sup> Michael Hinczewski<sup>b</sup> and Umut A. Gurkan <sup>1</sup><sup>b</sup>\*<sup>acf</sup>

Anemia affects over 25% of the world's population with the heaviest burden borne by women and children. Genetic hemoglobin (Hb) variants, such as sickle cell disease, are among the major causes of anemia. Anemia and Hb variant are pathologically interrelated and have an overlapping geographical distribution. We present the first point-of-care (POC) platform to perform both anemia detection and Hb variant identification, using a single paper-based electrophoresis test. Feasibility of this new integrated diagnostic approach is demonstrated *via* testing individuals with anemia and/or sickle cell disease. Hemoglobin level determination is performed by an artificial neural network (ANN) based machine learning algorithm, which achieves a mean absolute error of 0.55 g dL<sup>-1</sup> and a bias of -0.10 g dL<sup>-1</sup> against the gold standard (95% limits of agreement: 1.5 g dL<sup>-1</sup>) from Bland–Altman analysis on the test set. Resultant anemia detection is achieved with 100% sensitivity and specificity. With the same tests, subjects with sickle cell disease were identified with 100% sensitivity and specificity. Overall, the presented platform enabled, for the first time, integrated anemia detection and hemoglobin variant identification using a single point-of-care test.

children,<sup>5</sup> and poor birth outcomes,<sup>6,7</sup> and, decreased work productivity in adults.<sup>8</sup>

Genetic Hb disorders, such as sickle cell disease (SCD), are among the major causes for anemia globally.<sup>1,9</sup> Inherited Hb disorders afflict nearly 7% of the world's population, with most structural Hb variants having the recessive  $\beta$ -globin gene mutations,  $\beta^{S}$  (Hb S) and  $\beta^{C}$  (Hb C).<sup>10–12</sup> SCD arises when these mutations are inherited homozygously (Hb SS, SCD-SS) or paired with another  $\beta$ -globin gene mutation, such as hemoglobin C (Hb SC or SCD-SC).

Anemia and Hb variant are pathologically interrelated and have an overlapping geographical distribution. Under deoxygenation, sickle hemoglobin polymerizes, which induces the sickling of red blood cells (RBCs). Sickled RBCs have increased rigidity and fragility and are prone to intravascular hemolysis, leading to chronic hemolytic anemia, vasculopathy, and increased morbidity and mortality. Anemia and SCD have an overlapping pathophysiology and geographical distribution, causing high morbidity and mortality predominantly in resource-constrained regions of sub-Saharan Africa and South-east Asia.<sup>13–15</sup>

Anemia and SCD-related complications can be mitigated by early diagnosis followed by timely intervention.<sup>16–20</sup> Anemia treatment depends on the accurate characterization of the cause, such as inherited Hb disorders.<sup>21,22</sup> Meanwhile, Hb disorders such as SCD benefit from close monitoring of

<sup>&</sup>lt;sup>a</sup> Department of Mechanical and Aerospace Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA. E-mail: umut@case.edu; Web: https://case.edu/engineering/labs/bml/; Tel: +1 (216) 368 6447

 <sup>&</sup>lt;sup>b</sup> Department of Physics, Case Western Reserve University, Cleveland, OH 44106, USA
 <sup>c</sup> Department of Biomedical Engineering, Case Western Reserve University,

Cleveland, OH 44106, USA <sup>d</sup> Department of Pediatrics, Division of Hematology and Oncology, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

<sup>&</sup>lt;sup>e</sup> Division of Hematology & UNC Blood Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

<sup>&</sup>lt;sup>f</sup> Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA

 $<sup>\</sup>dagger$  Electronic supplementary information (ESI) available. See DOI: 10.1039/ d1lc00371b

#### Paper

blood Hb levels during treatment.<sup>20</sup> As a result, it is uniquely valuable to integrate analyses of blood Hb levels, *i.e.*, anemia status, and of Hb variants, especially in sub-Saharan Africa and India where anemia and inherited Hb disorders are the most prevalent.<sup>23</sup> Blood Hb level (in g dL<sup>-1</sup>) is used as the

indicator of anemia,<sup>24</sup> while the presence of Hb variants in blood is the primary indicator of an inherited disorder.<sup>25</sup> In resource-rich countries, standard clinical laboratory tests, including complete blood counts (CBCs) and highperformance liquid chromatography (HPLC), are typically



**Fig. 1** POC microchip electrophoresis for integrated anemia and hemoglobin variant testing. (A) HbVA cartridge consists of: (1) a plastic top cover, (2) a strip of cellulose acetate (CA) paper, (3) a pair of blotting pads, (4) embedded stainless-steel round electrodes, and (5) a plastic bottom part. Top and bottom plastic parts were injection molded. (B) HbVA cartridge design allows high volume manufacturing and assembly for affordability and single use. (C) A custom designed stamper and stamper stand pair is utilized to achieve reproducible blood sample application into the HbVA cartridge. (D) HbVA cartridge was placed under the stamper stand and the blood sample was applied to the cartridge using the stamper in a single step. (E) HbVA portable battery-operated reader unit accommodated the cartridge and ran the built software and the image analysis algorithm that tracked and analyzed the electrophoresis process in real-time. (F) A schematic representation of the HbVA test process is shown. First, a drop of blood (red) was mixed with standard calibrator (xylene cyanol, blue) and applied on the CA paper in the cartridge (t = 0). Within the first 2.5 minutes ( $t \le 2.5$  min), the total Hb (red) and standard calibrator (blue) were electrophoretically separated, at which time blood Hb level (g dL<sup>-1</sup>) and anemia status was determined by the algorithm. Next, Hb variant separation occurred ( $t \le 8$  min), which is then analyzed to determine the presence of major hemoglobin variants and types in the blood sample (*i.e.*, Hb A, F, S, and C). The entire electrophoresis process was tracked in real-time and the captured data was analyzed by the machine learning artificial neural network (ANN) algorithm for integrated blood Hb level determination, anemia detection, and Hb variant identification in a single test.

used in the diagnosis of anemia and inherited Hb disorders.<sup>24,25</sup> However, advanced laboratory techniques require trained personnel and state-of-the-art facilities, which are lacking in the very countries in which both anemia and Hb disorders are most prevalent.<sup>13,18</sup> Therefore, there is a need for affordable, portable, easy-to-use, accurate point-of-care tests that facilitate decentralized anemia detection and Hb variant identification.<sup>13,18,22,26</sup>

In a 2019 report, the World Health Organization (WHO) listed both anemia and sickle cell as the most essential *in vitro* diagnostic (IVD) tests needed for primary care use in low and middle income countries.<sup>27</sup> Point-of-care (POC) assays including HemoCue®,<sup>28</sup> AnemoCheck<sup>TM</sup>,<sup>29</sup> and smartphone based technologies<sup>30,31</sup> have been developed for anemia testing. Lateral flow assays including sickle SCAN<sup>32</sup> and HemoTypeSC<sup>33</sup> have been developed for Hb variant testing. However, these POC assays only enable individual detection of Hb level or Hb variant. Therefore, measurement of these two pathologically interconnected and geographically overlapping clinical endpoints require using of two distinct platforms.<sup>34</sup>

Hb electrophoresis has recently been added to the WHO essential list of IVDs for diagnosing SCD and sickle cell trait.<sup>35</sup> We have previously developed and extensively validated an affordable paper-based Hb electrophoresis platform, Hb variant (HbV) to conduct quantitative Hb variant detection.<sup>36</sup> HbV relied on osmotic blood lysing, manual sample loading, and measured Hb variant band intensity within a pre-defined region of interest in single captured image at pre-determined time point. As a result, HbV enabled quantitative determination of relative percentage (in %) for identified Hb variants.<sup>36</sup>

Accurate and reproducible anemia detection depends on accurate determination of absolute Hb level in blood. Here, we present an integrated point-of-care quantitative anemia and Hb variant test, the Hb variant-anemia (HbVA) test.<sup>37</sup> HbVA enables determination of absolute Hb level (in  $g dL^{-1}$ ) by further engineering our previously reported HbV system through: 1) using chemical-assisted blood lysing, 2) using customized sample loading system (Fig. 1), and 3) implementing an artificial neural network (ANN) based machine learning algorithm. The chemical-assisted blood lysing ensures release of all Hb molecules from the RBCs. The customized sample loading system provides consistent Hb and standard calibrator bands with controlled dimension and position. The ANN takes minimally processed intensity time series extracted from the raw image videos generated by the microchip electrophoresis POC platform, identifies salient features from the spectral pattern, and predicts a corresponding Hb level for the sample. We show the feasibility of this new diagnostic approach via a comprehensive test set comprising of 46 subjects, including individuals with or without anemia, and individuals with or without sickle cell disease (homozygous or heterozygous). We demonstrate that HbVA reproducibly and accurately determines blood Hb concentration with a mean absolute error of 0.55 g  $dL^{-1}$  and a bias of -0.10 g  $dL^{-1}$  (95% limits of agreement: 1.5 g dL<sup>-1</sup>) against the gold standard method according to Bland-Altman analysis. Resultant anemia determination was achieved

with 100% sensitivity and 92.3% specificity with a receiver operating characteristic area under the curve (AUC) of 0.99. Further, Hb variant determination is performed using the same method, leading to identification of subjects with sickle cell disease with 100% sensitivity and specificity. Overall, we show that HbVA platform enables, for the first time, reproducible, accurate, and integrated blood Hb level determination, anemia detection, and Hb variant identification in a single integrated POC test.

### Results

HbVA performs 2-step electrophoresis in a single test tracked by real-time imaging. The fundamental principle behind the HbVA technology is of Hb electrophoresis, in which different (bio)molecules including total hemoglobin, standard calibrator, and hemoglobin variants can be separated based on their charge-to-mass ratio when exposed to an electric field in the presence of a carrier substrate.37 HbVA is single-use and cartridge-based, which can be mass-produced at low-cost (Fig. 1A and B). The HbVA test works with a standard fingerprick or a heel-prick blood sample that is collected according to the World Health Organization (WHO) guidelines for drawing blood, which typically yields about 25 µL per drop.38 The sampled blood is mixed and lysed with a customized standard calibrator solution. A customized sample stamper set including stamper and stamper stand (Fig. 1C) is used to transfer the mixture containing lysed blood and standard calibrator into the cartridge for electrophoresis (Fig. 1D). Tris/ borate/EDTA (TBE) buffer is used to provide the necessary ions for electrical conductivity at a pH of 8.4 in the cellulose acetate paper.<sup>39,40</sup> The pH induced net negative charges of Hb and of standard calibrator molecules, causing them to travel from the negative to the positive electrode when placed in an electric field (Fig. 1F). HbVA performs a 2-step separation based on processing time (Fig. 1F and 2A). During the first step, the major mobility difference between total Hb and standard calibrator allows the total Hb including tested Hb variants to separates from the standard calibrator within a short period of time (<2.5 minutes) (Fig. 1F, middle-left and 2A  $t_0$  to  $t_{150}$ ). During the second step, the finer mobility differences among Hb variants allow them to separate (Fig. 1F, middle-right and 2A  $t_{150}$  to  $t_{480}$  and C, inset). The natural red visible hemoglobin, and naturally blue, visible standard calibrator (xylene cyanol), combined with optically clear HbVA cartridge in transmission mode within the reader's imaging chamber, obviate the need for picrosirius staining, which is otherwise utilized in benchtop cellulose acetate hemoglobin electrophoresis.39,40

# Integrated Hb level determination, anemia detection, and Hb variant identification in one single HbVA test

The HbVA 2-step electrophoresis separation is tracked in realtime (Fig. 2A–C), and analyzed using a two-step process according to the stage of separation. Briefly, for the first step (time  $t_0 \rightarrow t_{150}$ ), the algorithm tracks the relative Hb and calibrator band movements (Fig. 2A) within the ROI

Paper



Fig. 2 Overview of HbVA integrated hemoglobin level determination, anemia detection, and hemoglobin variant identification. (A) 2D space-time plot represents HbVA test band trajectory in time (*y*-axis) and space (*x* axis), visually illustrating the full electrophoretic band separation process across a whole video in a single image. Each pixel row of the image corresponds to a single one second frame, with time increasing from top (0 s) to bottom (480 s). For each point on the *x* axis we plotted the total intensities for the two-color bands (red = Hb and blue = standard calibrator), summed across the y range of the region of interest (ROI). The ROI was illustrated in the inset for a representative video frame. (B) The processing algorithm extracted the relative Hb and calibrator band information within the ROI by generating a relative intensity time series vector  $\rho(t)$  for t = 0 to 150 s, as input for the trained ANN. Process of computing  $\rho(t)$  demonstrated in (E) and (F) and also described in main text. (C) Hb variant was identified based on the final location Hb variant band at the end of the test (t = 480 s). (D) Individual frames within the ROI at 3 representative time points during HbVA test. At 60 s, detectable separation initiated between Hb band and standard calibrator band further separates thus increasing band separation resolution (middle frame  $\rho_{92} = 0.39$ ). At 150 s, total hemoglobin starts to separate into hemoglobin variants due to their minor mobility differences (bottom frame,  $\rho_{150} = 0.30$ ). (E) 3D intensity profile of Hb extracted from image acquired from frame at time slice t = 92 s (solid horizontal line in A and middle image in C). (F) An example pattern of time series vector  $\rho(t)$  including  $\rho_1$  to  $\rho_{150}$  recognized by the trained ANN.

(Fig. 2A inset). This is done by generating a time series of the relative intensity between Hb band and the standard calibrator band,  $\rho(t)$ , as input for a pre-trained ANN (Fig. 2B). The vector  $\rho(t)$  encoding the relatively intensity,  $\rho_i$ , is obtained from the information within ROI during the first 150 s in HbVA test (Fig. 2D). It is evaluated as the relative intensity ratio of the total Hb band intensity over total standard calibrator band intensity for each frame (Fig. 2E and F). The trained ANN extracts salient features from input  $\rho(t)$ , and performs regression analysis by associating these features with a Hb level in g dL<sup>-1</sup> and corresponding anemia status detection (Fig. 2B). The ANN has been pre trained on a training set comprising samples spanning a wide range of Hb levels, enabling anemia detection over a comparable range (Fig. 3A-L). This is followed by the second step of Hb variant identification. From the same test, late time  $(t_{150} \rightarrow t_{480})$  data is used to identify Hb variants using our previously published algorithm (Fig. 2C and 3M-T).<sup>36</sup> The HbVA algorithm tracks Hb variant band migration and identifies Hb variants based on their final locations at the end of test (Fig. 2C,  $t \le 8$  min).

In case of a single Hb variant detected, such as Hb SS (Fig. 3M and Q) vs. Hb AA (Fig. 3P and T), the HbVA algorithm reports a percentage value greater of >90%, which agrees with the results reported by the reference standard method (HPLC). If there is more than one peak identified, then the areas under each of the peaks are calculated and the relative percentages are reported, for example in the cases of Hb AS (Fig. 3N and R) and Hb SC (Fig. 3O and S).

#### Efficacy of ANN based Hb level determination

Hb level determination from HbVA video data was performed using a machine learning approach utilizing an ANN. Machine learning implementation details can be found in the Methods section. The efficacy of our network's performance has been validated using a standard repeated sub sampling validation routine. Details and results have been quoted in the ESI.† The final optimally trained network achieved 93.8% mean relative error (MRE) against the gold standard and Pearson correlation coefficient 0.95 on a test set of 46 samples.



Fig. 3 Integrated Hb level determination, anemia detection, and Hb variant identification in 4 representative tests on clinical samples with different Hb levels and Hb variants. (A-D) The first row includes 2D representation of HbVA test band trajectories. (E-H) The second row illustrates a representative frame for each test from the image arrays used to generate relative intensity ratio time series vectors  $\rho(t)$ , which are then utilized by the artificial neural network (ANN) to determine the Hb levels following the procedure outlined in Fig. 2. (I-L) The third row demonstrates the electropherogram corresponding to the image frames in the second row generated from the intensity profile envelopes. The Hb levels determined by HbVA (red) are compared against the reference method complete blood count (CBC) reported results. (M-P) The fourth row demonstrates the frames utilized to identify Hb variants. (Q-T) The fifth row demonstrates the electropherogram generated according to the band information in the fourth row. Each column represents HbVA test result for each patient. First column: HbVA test result for patient at Hb level of 6.0 q dL<sup>-1</sup> and with homozygous HbSS (sickle cell disease, SCD patient); second column: HbVA test result for patient at Hb level of 10.3 g dL<sup>-1</sup> and with heterozygous HbAS (SCD patient undergoing transfusion therapy); third column: HbVA test result for patient at Hb level of 12.7 g dL<sup>-1</sup> and with heterozygous Hb SC disease (hemoglobin C disease); fourth column: HbVA test results for a subject with Hb level of 14.5 g dL<sup>-1</sup> and with homozygous HbAA (healthy control). The HbVA Hb level determination and anemia detection results are compared against the reference method, complete blood count (CBC), reported results. The Hb variant identified by HbVA are compared against the reference method, high performance liquid chromatography (HPLC), reported results. HbVA demonstrated agreement in Hb level determination, anemia detection and Hb variant identification with reference standard methods CBC and HPLC (patient 1: HbVA: 5.8 g dL<sup>-1</sup>, anemia, Hb SS vs. CBC & HPLC: 6.0 g dL<sup>-1</sup>, anemia, Hb SS; patient 2: HbVA: 9.6 g dL<sup>-1</sup>, anemia, Hb AS vs. CBC & HPLC: 10.3 g dL<sup>-1</sup>, anemia, Hb AS; patient 3: HbVA: 12.8 g dL<sup>-1</sup>, anemia, Hb SC vs. CBC & HPLC: 12.7 g dL<sup>-1</sup>, anemia, Hb SC; patient 4: HbVA: 13.8 g dL<sup>-1</sup>, non-anemia, Hb AA vs. CBC & HPLC: 14.5 g dL<sup>-1</sup>, non-anemia, Hb AA). These results demonstrate HbVA's integrated blood Hb level determination and Hb variant identification.

#### HbVA tests are repeatable and agnostic to user variance

HbVA utilizes a blue standard calibrator with consistent charge-to-mass ratio at the test pH of 8.4. Utilization of relative Hb intensity over standard calibrator intensity as ANN input for Hb level determination compensates for user variance and enhances test repeatability (Fig. 4A, user 1 vs.

user 2). Among the 10 repeated tests (Fig. 4A), HbVA determined consistent Hb levels by 2 users (Fig. 5A, mean  $\pm$  SD (user 1 *vs.* user 2), = 11.99  $\pm$  0.55 *vs.* 12.35  $\pm$  0.45, coefficient of variance (COV) = 4.2%). Additionally, all 10 tests demonstrated agreement within  $\pm$ 1.0 g dL<sup>-1</sup> with the 12.7 g dL<sup>-1</sup> Hb level reported by reference standard of complete blood count (CBC). These results indicate that



Fig. 4 Repeatability and reproducibility of hemoglobin variant/anemia (HbVA) test: (A) repeatability of HbVA Hb level determination was tested with 10 repeated tests using the same sample, comparing variances between 2 users (demonstrated in the inset figures). The determined Hb levels between 2 users demonstrate strong repeatability (mean  $\pm$  SD (user 1 vs. user 2), = 11.99  $\pm$  0.55 vs. 12.35  $\pm$  0.45, coefficient of variance (COV) = 4.2%). All 10 repeated tests demonstrated agreement within  $\pm$ 1.0 g dL<sup>-1</sup> with the 12.7 g dL<sup>-1</sup> Hb level reported by reference standard of complete blood count (CBC). (B) Reproducibility of HbVA Hb level determination was tested using 3 samples each with very low, low and normal Hb levels reported from CBC. Each sample was tested 3 times by both HbVA and CBC. The standard deviation of HbVA determined Hb levels were within 4% COV across very low, low and normal Hb levels (mean  $\pm$  SD and COV for low, middle and high Hb levels: 6.1  $\pm$  0.2 g dl<sup>-1</sup>, 3.8%; 10.5  $\pm$  0.1 g dL<sup>-1</sup>, 1.0%; and 14.0  $\pm$  0.3 g dl<sup>-1</sup>, 2.1%, respectively, n = 3 for each sample). HbVA determined Hb levels also demonstrated excellent accuracy within  $\pm$ 0.6 g dL<sup>-1</sup> and  $\pm$ 5.0% with the CBC reported comparing to CBC reported data.

HbVA determines Hb level and detects anemia repeatable and are agnostic to user variance.

#### HbVA reproducibly determines Hb level for anemia detection

We performed reproducibility testing using 3 samples at different Hb ranges (sample 1: 6.0 g dL<sup>-1</sup> ( $\leq$ 9.0 g dL<sup>-1</sup>, very low Hb), sample 2: 10.4 g dL<sup>-1</sup> (within 9.1–12.0 g dL<sup>-1</sup>, low Hb level) and sample 3: 14.6 g dL<sup>-1</sup> (within 12.1–17.0 g dL<sup>-1</sup>, normal Hb level)).<sup>41</sup> Each sample was tested 3 times using both HbVA and the reference standard method CBC. HbVA

determined Hb level consistently over all 3 tested samples (Fig. 4B). The standard deviations among individual tests were  $\pm 0.2$  g dL<sup>-1</sup>,  $\pm 0.1$  g dL<sup>-1</sup> and  $\pm 0.3$  g dL<sup>-1</sup> (coefficient of variation (COV) = 3.8%, 1.0% and 1.8%, respectively) for samples at Hb level of sample 1, 2, and 3, respectively (Fig. 4B). In addition, HbVA determined Hb levels were within  $\pm 0.6$  g dL<sup>-1</sup> (<5%) when compared with CBC results demonstrating consistent agreement with the reference standard over the inspected Hb level range. These results indicate that HbVA determines Hb levels reproducibly over very low, low and normal Hb levels.



**Fig. 5** Hemoglobin variant/anemia (HbVA) artificial neural network (ANN) based machine learning algorithm accurately determines Hb levels and anemia status. (A) HbVA measured blood Hb levels strongly associated with CBC measured results (PCC = 0.95, p < 0.001). The dashed gray line represents the ideal result where HbVA Hb level is equal to the CBC Hb level whereas solid line represents the actual data fit. (B) Bland–Altman analysis revealed that HbVA determines blood Hb levels to within ±0.55 of the Hb level (absolute mean error) with minimal experimental bias with -0.1 g dL<sup>-1</sup>, indicating low bias. The dashed light gray line represents the relationship between the residual and the average Hb level measurements obtained from the CBC and HBVA (r = -0.07). The dashed dark grey line represented 95% limits of agreement (±1.5 g dL<sup>-1</sup>). (C) The receiver-operating characteristic (ROC) analysis graphically illustrates HbVA's performance against a random guess (grey line), with an area under the curve of 0.99, and a perfect diagnostic performance (green lines), with an area under the curve of 1. The area under the curve of 0.99 demonstrates HbVA's outstanding diagnostic performance (n = 46).

#### Lab on a Chip

 $\label{eq:table_$ 

Anemia <i>vs.</i> non-anemia (cut-off: 11.0 g $dL^{-1}$ )	
True positive, TP	33
True negative, TN	12
False positive, FP	$1^a$
False negative, FN	0
Sensitivity, $TP/(TP + FN)$	100%
Specificity, TN/(TN + FP)	92.30%

<sup>*a*</sup> False positive: CBC reported Hb level = 11.6 g dL<sup>-1</sup> while HbVA determined Hb level = 10.4 g dL<sup>-1</sup>.

#### HbVA determines Hb level accurately

The scatter plot includes the ANN determined Hb levels by HbVA (y axis) versus the Hb levels reported by the standard reference (CBC) within 46 tested samples with a variety of Hb variants and healthy subjects (Fig. 5A). Our results demonstrate a Pearson correlation coefficient (PCC) of 0.95, p < 0.001 revealing strong association between HbVA determined Hb levels and CBC reported Hb levels (Fig. 5A). Bland-Altman analysis showed that HbVA determines blood Hb levels with a mean absolute error of 0.55 g  $dL^{-1}$  and a bias of  $-0.10 \text{ g dL}^{-1}$  (95% limits of agreement: 1.5 g dL<sup>-1</sup>) in 46 patients (Fig. 5B). The receiver-operating characteristic analysis revealed that HbVA achieves a strong performance with an area under the curve of 0.99 (Fig. 5C) and highlights the accuracy of HbVA through the entire range of tested Hb levels (6.0-15.3 g dL<sup>-1</sup>). Hb levels and HbVA measured residual (r = -0.07) showed that HbVA performance remained consistent throughout the range of tested Hb level (Fig. 5B), this degree of accuracy is on par with reported accuracy values in POC settings of other clinically used single-function anemia detection devices.28,42

# HbVA performs integrated anemia detection and Hb variant identification with high sensitivity and specificity

We investigated the sensitivity and specificity of HbVA anemia detection from ANN determined Hb levels, using single Hb cutoff level of 11.0 g dL<sup>-1</sup> to differentiate anemia and non-anemia subjects. Hb level at <11.0 g dL<sup>-1</sup> is a well-established threshold for defining anemia.<sup>43</sup> The sensitivity and specificity of HbVA to detect anemia was 100% and 92.3% (95% CI, 84.6–100%), respectively (Table 1). The high sensitivity and specificity indicate the potential for this test to serve as an integrated assessment tool for anemia

screening and diagnosis. We investigated the sensitivity and specificity of HbVA Hb variant identification by comparing HbVA identified Hb variant with standard reference method HPLC reported results. Overall, HbVA demonstrated 100% sensitivity and specificity on identifying Hb variants including HbSS, HbAS, HbSC and HbAA among the 46 subjects tested, using the results from the same tests for Hb level measurement and anemia detection (Table 2).

# Diagnostic profile of HbVA integrated Hb level determination, anemia detection and Hb variant identification

Overall, 7 healthy subjects (HbAA), 6 subjects with Hb SC, 5 sickle beta+ thalassemia (HbSBeta+) patients, and 28 SCD (HbSS) patients were tested (Fig. 5A). It should be noted that 21 of the 28 SCD patients tested in this study were on exchange transfusion therapy thus their Hb variants were identified as a mix of HbA and HbS by both the HbVA and standard reference method HPLC. Among the 46 tested patients, HbVA demonstrated high accuracy in Hb level determination as well as high sensitivity and specificity in both anemia detection as well as in Hb variant identification, compared with the reference CBC and HPLC.

### Discussion

Timely and effective treatments are available for anemia upon early detection and the treatment methods are highly dependent on the causes of anemia, including but not limited to nutritional deficiencies, malaria, and Hb disorders. Therefore, anemia detection is often carried out along with identification/screening procedures of other diseases. For example, a policy in Kenya states that women should be tested for anemia, HIV, syphilis, and malaria at first antenatal care.<sup>44</sup>

Iron deficiency and SCD are among the most prevalent causes for anemia in low resource settings. Iron deficiency anemia can be treated with iron supplements or blood transfusion.<sup>45</sup> Current treatment and emerging therapies for SCD include blood transfusion, hydroxyurea, crizanlizumab, and voxelotor,<sup>46,47</sup> and are becoming more available for low-resource settings. However, high intracellular iron in patients with SCD are associated with markers of inflammation and mortality,<sup>48</sup> thus therapeutic or supplemental iron may have adverse clinical consequences in patients with SCD and unnecessary transfusions therefore are strongly suggested to be minimized.<sup>49,50</sup> The goal of therapeutic interventions for patients with SCD is to maintain the HbS% below a target

Table 2	Sensitivity and	specificity	of Hb	variant/anemia	on	Hb	variant	identification
---------	-----------------	-------------	-------	----------------	----	----	---------	----------------

	Hb SS vs. others	Hb SC vs. others	Hb AA vs. others
True positive, TP	9	6	7
True negative, TN	37	40	39
False positive, FP	0	0	0
False negative, FN	0	0	0
Sensitivity, TP/(TP + FN)	100%	100%	100%
Specificity, TN/(TN + FP)	100%	100%	100%

#### Paper

threshold to reduce SCD-related complications.<sup>51</sup> As a result, application of transfusion therapy for patients with SCD requires careful consideration of multiple biomarkers including Hb level and percentage of hemoglobin S (HbS%).<sup>51,52</sup> Furthermore, both Hb level and HbS% are critical clinical endpoints for evaluating of the efficacy of hydroxyurea in treating SCD.<sup>53</sup> Together, early, accurate and simultaneous diagnosis, as well as consistent monitoring of both anemia and Hb disorders is essential to facilitate timely lifesaving interventions, especially in low- and middle-income countries, where anemia and Hb disorders are most prevalent. In fact, a recent study has been performed in Tanzania to detect anemia and SCD using two monofunctional POC devices for detecting individual disease.<sup>34</sup>

Many commercially available point-of-care (POC) assays including the WHO Haemoglobin Colour Scale, HemoCue®, DiaSpectTM, Mission® Hemoglobin Plus, and AnemoCheck™, Haemospect®, and NBM-200, as well as various emerging POC assays and smartphone based technologies are in the horizon for performing individual diagnosis of anemia (Table 3).<sup>30,54-62</sup> Several POC assays including hemoglobin solubility test, density test, and lateral flow assays including sickle SCAN, and HemoTypeSC are available for individual diagnosis of SCD (Table 3).63-69 These technologies provide POC solutions for individual diagnosis of anemia and SCD, and have been tested and validated as summarized in our previous review articles.<sup>26,70</sup> However, these POC assays so far only focus on detection of a single disease, while none of them is capable of integrated detection of both anemia and SCD using a single assay.

Previously, we leveraged the WHO recommended Hb electrophoresis to develop an affordable paper-based Hb electrophoresis platform, HbV, for single function Hb variant identification.<sup>36</sup> HbV's Hb variant identification capability has been extensively validated in multiple locations using >700 clinical patient samples and has demonstrated its capability to identify and quantify the relative percentage (%) of Hb variants, with the goal of establishing a clinical standard test for Hb variant screening and diagnosis worldwide.<sup>36</sup>

In this work, we improved the paper-based electrophoresis platform from various engineering perspectives including hardware, reagent, and software algorithm. These advances (in lysing, stamper set, dynamic LOI determination, machine learning recognition of Hb patterns) enabled accurate quantification of absolute level of total Hb (in g dL<sup>-1</sup>) and anemia detection, in addition to the previously validated Hb variant identification. To our knowledge, HbVA is the first POC device providing integrated Hb level determination, anemia detection, and Hb variant identification.

Here, we determined Hb level by comparing Hb band intensity to the intensity of the standard calibrator. This is established on the foundation that the standard calibrator has consistent and significantly different electric mobility from Hbs, at the test pH of 8.4. This mobility difference allows the total Hb band to be separated from the standard calibrator band within a short period of time ( $\leq$ 2.5 min), before the Hb variants start separating.

Compared to relative percentage of Hb variant, determination of absolute level of total Hb level requires complete lysing of RBCs in whole blood. The customized standard calibration solution utilized here demonstrated >99.99% lysing of RBCs. This lysing efficiency of the improved solution is significantly higher than the lysing efficiency achieved previously, without inducing any noticeable alteration on Hb molecule electrophoretic property.

Reproducible and accurate determination of total Hb level depends on consistently generated quantifiable Hb band and standard calibrator band for samples at a range of Hb levels. Compared to the previous Hb quantification system, the sample applicator has reduced width and sample volume holding capacity. This improved sample applicator design constrained the loaded sample to maintain >2.5 mm margin from the edge of CA paper. This margin reduces the impact of band diffusion and CA paper saturation on Hb and standard calibrator bands quantification. Additionally, the customized sample stamper and stamper stand control the total volume and position of the loaded sample, providing efficient tool for consistent sample loading which can potentially reduce both test variance and user variance, especially in rapid clinical test at the point of care.

The ANN based machine learning algorithm leveraged in this study is essential for real-time tracking of the electrophoresis band separation process and extracting salient features from the data for accurate determination of

Table 3      Comparison of available anemia diagnostic technologies with Hb variant/anemia							
Technology		Hb variant	Low cost	Accuracy <sup>a</sup>	Reproducibility	Ref.	
Complete blood count (standard reference)	1	x	x	1	1	24	
HemoCue	$\checkmark$	X	$\checkmark$	$\checkmark$	$\checkmark$	28	
WHO color scale	$\checkmark$	X	$\checkmark$	X	$\checkmark$	77	
Non-invasive methods (including smart phone-based technologies)	$\checkmark$	X	$\checkmark$	X	X	28	
HPLC (standard reference)	X	$\checkmark$	x	$\checkmark$	$\checkmark$	78	
Paper-based hemoglobin solubility	X	$\checkmark^a$	$\checkmark$	$\checkmark$	$\checkmark$	63	
Density-based HbS detection	X	$\checkmark^a$	$\checkmark$	$\checkmark$	$\checkmark$	79	
Sickle SCAN	X	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	32	
HemoTypeSC	X	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	33	
Hb variant/anemia (HbVA)	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	This paper	

<sup>a</sup> Only distinguishes Hb S from Hb A, does not distinguish other Hb variants such as Hb C.

Hb level and anemia detection. The algorithm extracts the dynamics of relative Hb to calibrator band position within the ROI. The band information is tracked in real-time to evaluate the relative intensity ratio of the total Hb band intensity over total standard calibrator to generate a time series vector  $\rho(t)$ , as input for the trained ANN the ANN examines this relative intensity time series spectrum to extract the dynamics of relative Hb to calibrator band position within the ROI. Additionally, the learning-oriented approach implemented in HbVA holds the perquisite of being flexible to ANN re-training and algorithm upgrade. Future increased test population will augment the current data set enabling ANN re-training and further tuning and enhancement of network performance.

Clinical testing of HbVA demonstrated accurately determined blood Hb concentration with low error and bias, according to Bland–Altman analysis. Anemia determination was achieved with high sensitivity and specificity with a receiver operating characteristic area under the curve (AUC) of 0.99. In addition to the new feature of Hb level determination and anemia detection, HbVA maintained its performance on Hb variant identification demonstrating 100% sensitivity and specificity identifying SCD.

A potential limitation of this study is that tested population was focused on patients with inherited hemoglobin disorders, who are typically anemic. Future studies will expand the test population by including higher number of healthy subjects with higher Hb levels. This system also shares the common limitation as other electrophoresis techniques for the function of Hb variant identification. Some Hb types appear in the same electrophoretic window, as they exhibit similar charge to mass ratio thus electrophoretic mobility in a given condition,<sup>71,72</sup> which may be improved using curve fitting methods. For example, Hb G and Hb D are difficult to separate because they have identical migration in gel electrophoresis, in capillary electrophoresis, and they have overlapping elution times in HPLC. This sharing of detection window or peak overlapping is also a challenge for the reference standard method, HPLC as well as its alternatives.<sup>71,73,74</sup>

In summary, we show that merging engineering innovation and machine learning algorithms can be used to quantitatively measure Hb levels in paper-based electrophoresis, enabling, for the first time, reproducible, accurate, and integrated anemia detection and Hb variant identification in a single test at the point-of-care. HbVA is a versatile and mass-producible microchip electrophoresis platform technology that may address unmet needs in biology and medicine, when rapid, decentralized Hb or protein analyses are needed.

### Methods

#### Fully integrated microchip electrophoresis cartridge

The machine learning assisted HbVA cellulose acetate paperbased microchip electrophoresis system (Fig. 1) facilities, integrated Hb level determination, anemia detection and Hb variant identification (Video S1<sup>†</sup>). The HbVA cartridge is manufactured using two injection molded plastic parts made of Optix® CA-41 polymethyl methacrylate acrylic (Fig. 1A-1 and A-5). The injection molded HbVA cartridge embodies a pair of round corrosion-resistant, biomedical grade electrodes made of 316 stainless steel 316. The electrode pair is in direct contact to the electrophoresis buffer solution connected to the cellulose acetate paper strip in the buffer pools housed in the cartridge (Fig. 1A and B). One corner of the HemeChip cartridge is chamfered to facilitate correct orientation during use (Fig. 1A and B).

#### Repeatability and reproducibility of HbVA

We first tested HbVA's repeatability by performing 10 repeated tests using same sample. The 10 tests were performed by 2 users with 5 tests each and compared for user variance. In addition, we tested HbVA's reproducibility over very low, low and normal Hb level ranges. We performed reproducibility test using 3 samples at different Hb levels. Each sample was tested 3 times using both HbVA and reference standard method CBC of 6.0 g dL<sup>-1</sup> ( $\leq$ 9.0 g dL<sup>-1</sup>, very low Hb level), 10.4 g dL<sup>-1</sup> (within 9.1–12.0 g dL<sup>-1</sup>, low Hb level) and 14.6 g dL<sup>-1</sup> (within 12.1–17.0 g dL<sup>-1</sup>, normal Hb level).

#### Materials and reagents

1× Tris/borate/EDTA (TBE) buffer at pH 8.4 was used as background electrolyte for electrophoresis, reconstituted from 10× TBE buffer (ThermoFisher Scientific, Waltham, MA). Whole blood lysing buffer was prepared using ultrapure water (ThermoFisher Scientific, Waltham, MA) and customized standard calibrator (a fiducial marker that is negatively charged at pH 8.4) with 0.01% saponin and was used to perform whole blood lysing to release Hb from red blood cells.

# HbVA test for integrated Hb level determination, anemia detection and Hb variant identification

The HbVA test can be performed by minimally trained personnel to produce fast, accurate, and reproducible results. The complete procedure consists of three steps: (i) chip preparation, (ii) sample preparation, (iii) Hb separation (10 minutes), followed by machine learning ANN algorithm-based data analysis. Briefly, cellulose acetate paper within HbVA cartridge is wetted by introducing 40 µL background electrolyte. The cartridge is positioned onto the customized stamper. Sample is prepared by diluting whole blood sample into customized standard calibrator solution at 2:1. The calibrator solution is composed of electrophoresis marker xylene cyanol (molecular weight: 538.61 g mol<sup>-1</sup>, Sigma Aldrich). The mixed sample is then loaded into wetted cellulose acetate paper using the customized stamper toolset. Finally, 200 µL background electrolyte is injected into the buffer ports at each end of the cartridge to provide sufficient contact between electrode-electrolyte-paper to complete circuit connection and provide stable current for electrophoresis. The

HbVA integrated tests involve 2 steps separation in progression with time. The step 1 separation takes place within 3 minutes after initiation of separation process. During the short separation time, step 1 separates total Hb (red) from lysed blood from the applied standard calibrator (blue) (Fig. 1F, middle-left and 2A) due to the major mass-to-charge ratio between Hb and standard calibrator. Region of interest (ROI) is defined by the algorithm. Within the ROI, the relative intensity ratio of the total Hb band intensity over total standard calibrator band intensity is evaluated by  $\rho_i$  ( $\rho_{92} = 0.39$  for demonstrated frame in Fig. 2B at t = 92 s). The electrophoresis separation process within ROI is tracked for the first 150 frames (Fig. 2C) and the relative intensity ratio  $\rho_i$  is then calculated for the first 150 frames after HbVA test initiation (Fig. 2D) tracking the relative Hb band intensity to generate a time series vector  $\rho(t)$  (Fig. 2E). The obtained  $\rho(t)$  is then input to a trained artificial neural network (ANN) which performs regression by examining underlying time series data to determine the Hb level. The step 2 separation takes place between 3-10 minutes during HbVA process (Fig. 2F). As separation time progresses, step 2 separates total Hb into individual Hb subtypes according to their finer mass-to-charge ration among various Hb subtypes. After 10 minutes, the test is stopped automatically by the reader software.

#### **Clinical testing of HbVA**

Clinical study design, study participants, sample size calculation, and details on test methods are designed according to the Reference and Selected Procedures for the Quantitative Determination of Hb in Blood; Approved Standard - Third Edition (H15-A3) published by the CLSI.41,75 We tested 46 samples including 37 clinical patient samples and 9 healthy subject samples. Since the focus of HbVA is to perform integrated anemia detection (reflected by low Hb level) and Hb variant identification, we mainly examined samples from SCD patients most of whom were anemic. Among 46 patients, 17 tested samples (37% of the total tested samples) were within the very low Hb range of  $\leq 9.0$  g dL<sup>-1</sup>; 19 tested samples (41% of the total tested samples) were within the low Hb range of 9.1–12.0 g  $dL^{-1}$ ; and 11 tested samples (22% of the total tested samples) are within Hb level range of 12.1-17.0 g dL<sup>-1</sup>. Institutional Review Board (IRB) approved protocols included the following common objectives: to validate HbVA technology as a point-of-care platform for Hb testing, to compare the screening results obtained from HbVA with that obtained from laboratory CBC and HPLC as the standard reference methods, to determine the diagnostic accuracy of the test including sensitivity and the specificity, and to determine the feasibility of using HbVA as a point-of-care testing platform in low and middle income countries. All experiments were performed in compliance with the study protocol approved by the IRB committee at University Hospitals Cleveland Medical Center (UHCMC IRB# 04-17-15). Study participants were fully informed regarding the purposes of the study and consent was obtained.

#### Statistical methods

Statistical significance (p < 0.05) was determined via two-tailed Student's t-test assuming unequal variance. All statistical tests (calculation of regression correlation coefficients and Student's t-tests) were conducted using Minitab 17 Statistical software. 95% confidence intervals for sensitivity and specificity are calculated according to the efficient-score method. The Bland-Altman method was used to determine the repeatability of HbVA Hb determination using residual analysis by comparison to the standard reference method. The coefficient of repeatability was set as 1.96 times the standard deviations of the differences between the two measurements. Sensitivity was determined as the ratio of true positive results divided by the summation of true positive results and false negative results. Specificity was determined as the ratio of true negative results divided by the summation of true negative results and false positive results.

# Machine learning for Hb level determination: ANN implementation

The machine learning processing pipeline was established using the open source Keras machine learning library on top of a TensorFlow backend.76 The workflow can be deconstructed into the following steps, also illustrated for a representative HbVA test in Fig. 2 and ESI<sup>†</sup> Video (ESI<sup>†</sup> Video S1): 1) region of interest (ROI), is carefully defined to capture all relevant pixel information for both Hb band (red) and standard calibrator band (blue). Each frame from the video is sequentially split into its constituent red and blue channels. 2) The spatial summed relative intensity between red channel and blue channels ( $\rho_i = (\sum_{Y \sum X})_{\text{Red}} / (\sum_{Y \sum X})_{\text{Blue}}$ , Fig. 2E) is calculated for each frame from time 0 to 150 s, monitoring the relative abundancy of total hemoglobin and standard calibrator within that time period, to construct a relative intensity time series vector  $\rho(t)$  (Fig. 2F).  $\rho(t)$  is fed as the input feature vector to a trained artificial neural network (ANN) that examines the intensity ratio pattern and reports the corresponding Hb level in g  $dL^{-1}$  (Fig. 2B). The result is used to determine the anemia status of the test subject according to the standard.

The ANN in our workflow has been developed for a Python environment. To implement this regression problem, we used a standard vanilla feedforward network with constituent perceptron units. The constructed ANN has three densely connected layers- an input layer, a hidden dense layer, and an output layer. The input and hidden layers each have 32 nodes with rectified linear unit (ReLU) activations. The ANN takes the pre-processed relative intensity ratio time series vector  $\rho(t)$  as input feature vector. For the size of our choice of input vector  $\rho(t)$ , this corresponds to 5921 trainable parameters in the network. The network was trained and tested on a comprehensive data set of 68 HbVA tests. The training set consisted of 27 samples, out of which 4 were further split into a validation set (i.e. 15% of training set). The remaining 41 samples were kept aside for the test set, and later augmented by a further set of 5 samples to make up a combined test set of 46 samples. Training was run on an NVIDIA GeForce RTX<sup>™</sup> 2060 GPU. Assuming the error in the input data CBC responses to be normally distributed, we chose the mean squared logarithmic error (MSLE) as our choice of loss function to minimize over the training process. To prevent overfitting- along with allocating 15% of our training set into a holdout validation set, we stopped training when the validation loss performance stopped changing over a set number of epochs. The optimal network reached an MSLE loss of 0.9% for training and 1.1% for validation. Further details about the efficacy testing of the ANN are shown in the ESI.†

# Data and materials availability

All reasonable requests for materials and data will be fulfilled by the corresponding author of this publication.

### Author contributions

RA and UAG conceived the idea. RA, YM, MNH, YH, SI contributed to the proof-of-concept experiments and initial development. AB, AH, SA, JAL helped with the planning and execution of clinical testing, including human subject research protocol development, subject recruitment, blood sample collection, and testing. RA, YM, SI, EK, UG, KC, ZS, MH, and UAG performed the data analysis, prepared the tables, figures, figure captions, and ESL<sup>†</sup> RA drafted the manuscript and all authors edited the manuscript. All authors read and/or edited the manuscript.

# Conflicts of interest

RA, JAL, UAG, and Case Western Reserve University have financial interests in Hemex Health Inc. JAL, EK, UAG, and Case Western Reserve University have financial interests in BioChip Labs Inc. UAG and Case Western Reserve University have financial interests in Xatek Inc. UAG has financial interests in DxNow Inc. Financial interests include licensed intellectual property, stock ownership, research funding, employment, and consulting. Hemex Health Inc. offers pointof-care diagnostics for hemoglobin disorders, anemia, and malaria. BioChip Labs Inc. offers commercial clinical microfluidic biomarker assays for inherited or acquired blood disorders. Xatek Inc. offers point-of-care global assays to evaluate the hemostatic process. DxNow Inc. offers microfluidic and bio-imaging technologies for in vitro fertilization, forensics, and diagnostics. Competing interests of Case Western Reserve University employees are overseen and managed by the Conflict of Interests Committee according to a Conflict-of-Interest Management Plan.

## Acknowledgements

Authors acknowledge National Heart Lung and Blood Institute Small Business Innovation Research Program (R44HL140739, R41HL151015), National Heart Lung and Blood and the National Center for Complementary & Integrative Health (NCCIH) U54HL143541, National Institute of Diabetes and Digestive and Kidney Diseases Small Business Innovation Research Program (R41DK119048), and National Heart Lung and Blood Institute R01HL133574 and T32HL134622. This article's contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

## References

- N. J. Kassebaum, R. Jasrasaria, M. Naghavi, S. K. Wulf, N. Johns, R. Lozano, M. Regan, D. Weatherall, D. P. Chou, T. P. Eisele, S. R. Flaxman, R. L. Pullan, S. J. Brooker and C. J. Murray, *Blood*, 2014, **123**, 615–624.
- 2 C. M. Chaparro and P. S. Suchdev, Ann. N. Y. Acad. Sci., 2019, 1450, 15-31.
- 3 The World Health Organization, *WHO Global Database on Anaemia*, 2008.
- 4 R. J. S. Magalhães and A. C. A. Clements, *Bull. W. H. O.*, 2011, **89**, 459–468.
- 5 S. P. Walker, T. D. Wachs, J. M. Gardner, B. Lozoff, G. A. Wasserman, E. Pollitt and J. A. Carter, *Lancet*, 2007, 369, 145–157.
- 6 B. A. Haider, I. Olofin, M. Wang, D. Spiegelman, M. Ezzati and W. W. Fawzi, *BMJ* [*Br. Med. J.*], 2013, **346**, f3443.
- 7 K. Rasmussen, J. Nutr., 2001, 131, 590S-601S; discussion 601S-603S.
- 8 J. D. Haas and T. T. Brownlie, *J. Nutr.*, 2001, **131**, 676S–688S; discussion 688S-690S.
- 9 R. Barnett, Lancet, 2017, 389, 998.
- 10 B. Modell and M. Darlison, Bull. W. H. O., 2008, 86, 480-487.
- 11 D. T. Jamison and W. Bank and D. C. P. Project, *Disease Control Priorities in Developing Countries*, Oxford University Press, 2006.
- 12 D. J. Weatherall and J. B. Clegg, *Bull. W. H. O.*, 2001, **79**, 704–712.
- 13 D. J. Weatherall, *Blood*, 2010, **115**, 4331–4336.
- 14 G. J. Kato, F. B. Piel, C. D. Reid, M. H. Gaston, K. Ohene-Frempong, L. Krishnamurti, W. R. Smith, J. A. Panepinto, D. J. Weatherall, F. F. Costa and E. P. Vichinsky, *Nat. Rev. Dis. Primers*, 2018, 4, 18010.
- 15 J. Mburu and I. Odame, Int. J. Lab. Hematol., 2019, 41, 82-88.
- 16 E. Vichinsky, D. Hurst, A. Earles, K. Kleman and B. Lubin, *Pediatrics*, 1988, **81**, 749–755.
- 17 T. Frempong and H. A. Pearson, Conn. Med., 2007, 71, 9–12.
- 18 J. Mburu and I. Odame, Int. J. Lab. Hematol., 2019, 41, 82-88.
- M. O. Quarmyne, W. Dong, R. Theodore, S. Anand, V. Barry, O. Adisa, I. D. Buchanan, J. Bost, R. C. Brown, C. H. Joiner and P. A. Lane, *Am. J. Hematol.*, 2017, **92**, 77–81.

- 20 L. Tshilolo, G. Tomlinson, T. N. Williams, B. Santos, P. Olupot-Olupot, A. Lane, B. Aygun, S. E. Stuber, T. S. Latham, P. T. McGann and R. E. Ware, *N. Engl. J. Med.*, 2019, 380, 121–131.
- 21 The World Health Organization, *Technical meeting: Use and interpretation of haemoglobin concentrations for assessing anaemia status in individuals and populations*, 2017.
- 22 The World Health Organization, *Nutritional anaemias: tools for effective prevention and control*, Licence: CC BY-NC-SA 3.0 IGO, 2017.
- 23 J. Howard and S. L. Thein, Hematology, 2019, 2019, 505-512.
- 24 C. A. Northrop-Clewes and D. I. Thurnham, J. Blood Med., 2013, 4, 11–22.
- 25 Centers for Disease Control and Prevention, Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up, 2015.
- 26 Y. Alapan, A. Fraiwan, E. Kucukal, M. N. Hasan, R. Ung, M. Kim, I. Odame, J. A. Little and U. A. Gurkan, *Expert Rev. Med. Devices*, 2016, 13, 1073–1093.
- 27 The World Health Organization, 2019, ((WHO Technical Report Series, No. 1017)).
- 28 L. Lamhaut, R. Apriotesei, X. Combes, M. Lejay, P. Carli and B. Vivien, *Anesthesiology*, 2011, **115**, 548–554.
- 29 M. S. Perez-Plazola, E. A. Tyburski, L. R. Smart, T. A. Howard, A. Pfeiffer, R. E. Ware, W. A. Lam and P. T. McGann, *BMC Med.*, 2020, **18**, 337.
- 30 R. G. Mannino, D. R. Myers, E. A. Tyburski, C. Caruso, J. Boudreaux, T. Leong, G. D. Clifford and W. A. Lam, *Nat. Commun.*, 2018, 9, 4924.
- 31 G. Dimauro, S. De Ruvo, F. Di Terlizzi, A. Ruggieri, V. Volpe, L. Colizzi and F. Girardi, *Electronics*, 2020, 9, 780.
- 32 J. Kanter, M. J. Telen, C. Hoppe, C. L. Roberts, J. S. Kim and X. Yang, *BMC Med.*, 2015, **13**, 225.
- 33 C. Steele, A. Sinski, J. Asibey, M.-D. Hardy-Dessources, G. Elana, C. Brennan, I. Odame, C. Hoppe, M. Geisberg, E. Serrao and C. T. Quinn, *Am. J. Hematol.*, 2019, 94, 39–45.
- 34 L. R. Smart, E. E. Ambrose, K. C. Raphael, A. Hokororo, E. Kamugisha, E. A. Tyburski, W. A. Lam, R. E. Ware and P. T. McGann, *Ann. Hematol.*, 2018, 97, 239–246.
- 35 The World Health Organization, (WHO/MVP/EMP/2019.05), 2019.
- 36 M. N. Hasan, A. Fraiwan, R. An, Y. Alapan, R. Ung, A. Akkus, J. Z. Xu, A. J. Rezac, N. J. Kocmich, M. S. Creary, T. Oginni, G. M. Olanipekun, F. Hassan-Hanga, B. W. Jibir, S. Gambo, A. K. Verma, P. K. Bharti, S. Riolueang, T. Ngimhung, T. Suksangpleng, P. Thota, G. Werner, R. Shanmugam, A. Das, V. Viprakasit, C. M. Piccone, J. A. Little, S. K. Obaro and U. A. Gurkan, *Analyst*, 2020, **145**, 2525–2542.
- 37 R. An, Y. Man, S. Iram, E. Kucukal, M. N. Hasan, A. Solis-Fuentes, A. Bode, A. Hill, K. Cheng, Y. Huang, S. Ahuja, J. A. Little, M. Hinczewski and U. A. Gurkan, *Blood*, 2020, 136, 46–47.
- 38 The World Health Organization, Available from: https://www. ncbi.nlm.nih.gov/books/NBK138650/, 2020.
- 39 B. J. Bain, Haemoglobinopathy Diagnosis, Wiley, 2005.

- 40 B. J. Bain, B. Wild, A. Stephens and L. Phelan, *Variant Haemoglobins: A Guide to Identification*, Wiley, 2011.
- 41 Clinical & Laboratory Standards Institute, *Reference and* Selected Procedures for the Quantitative Determination of Hemoglobin in Blood, 3rd edn, 2000.
- 42 H. Marn and J. A. Critchley, *Lancet Glob. Health*, 2016, 4, e251–e265.
- 43 I. H. Thaver and L. Baig, JPMA, J. Pak. Med. Assoc., 1994, 44, 282–284.
- 44 N. Young, M. Taetgmeyer, G. Zulaika, G. Aol, M. Desai, F. Ter Kuile and I. Langley, *BMC Public Health*, 2019, **19**, 1629.
- 45 K. Jimenez, S. Kulnigg-Dabsch and C. Gasche, *Gastroenterol. Hepatol.*, 2015, **11**, 241–250.
- 46 L. D. Neumayr, C. C. Hoppe and C. Brown, Am. J. Manag. Care, 2019, 25, S335–S343.
- 47 E. Vichinsky, C. C. Hoppe, K. I. Ataga, R. E. Ware, V. Nduba, A. El-Beshlawy, H. Hassab, M. M. Achebe, S. Alkindi, R. C. Brown, D. L. Diuguid, P. Telfer, D. A. Tsitsikas, A. Elghandour, V. R. Gordeuk, J. Kanter, M. R. Abboud, J. Lehrer-Graiwer, M. Tonda, A. Intondi, B. Tong and J. Howard, *N. Engl. J. Med.*, 2019, **381**, 509–519.
- 48 E. J. van Beers, Y. Yang, N. Raghavachari, X. Tian, D. T. Allen, J. S. Nichols, L. Mendelsohn, S. Nekhai, V. R. Gordeuk, J. G. Taylor and G. J. Kato, *Circ. Res.*, 2015, **116**, 298–306.
- 49 P. R. Koduri, Am. J. Hematol., 2003, 73, 59-63.
- 50 R. Raghupathy, D. Manwani and J. A. Little, *Adv. Hematol.*, 2010, **2010**, 272940.
- 51 S. T. Chou, M. Alsawas, R. M. Fasano, J. J. Field, J. E. Hendrickson, J. Howard, M. Kameka, J. L. Kwiatkowski, F. Pirenne, P. A. Shi, S. R. Stowell, S. L. Thein, C. M. Westhoff, T. E. Wong and E. A. Akl, *Blood Adv.*, 2020, 4, 327–355.
- 52 S. Uter, H. H. An, G. E. Linder, S. Kadauke, D. Sesok-Pizzini, H. C. Kim, D. F. Friedman and S. T. Chou, *Blood Adv.*, 2021, 5, 2586–2592.
- 53 C. C. John, R. O. Opoka, T. S. Latham, H. A. Hume, C. Nabaggala, P. Kasirye, C. M. Ndugwa, A. Lane and R. E. Ware, *N. Engl. J. Med.*, 2020, **382**, 2524–2533.
- 54 E. A. Tyburski, S. E. Gillespie, W. A. Stoy, R. G. Mannino, A. J. Weiss, A. F. Siu, R. H. Bulloch, K. Thota, A. Cardenas, W. Session, H. J. Khoury, S. O'Connor, S. T. Bunting, J. Boudreaux, C. R. Forest, M. Gaddh, T. Leong, L. A. Lyon and W. A. Lam, *J. Clin. Invest.*, 2014, **124**, 4387–4394.
- 55 P. T. McGann, E. A. Tyburski, V. de Oliveira, B. Santos, R. E. Ware and W. A. Lam, *Am. J. Hematol.*, 2015, **90**, 1122–1127.
- 56 J. Lee, J. Song, J.-H. Choi, S. Kim, U. Kim, V.-T. Nguyen, J.-S. Lee and C. Joo, *Sci. Rep.*, 2020, **10**, 8606.
- 57 F. Sanchis-Gomar, J. Cortell-Ballester, H. Pareja-Galeano, G. Banfi and G. Lippi, *J. Lab. Autom.*, 2013, **18**, 198–205.
- 58 L. G. T. Darshana and D. I. Uluwaduge, Anemia, 2014, 2014, 4.
- 59 R. Hiscock, D. Kumar and S. W. Simmons, *Anaesth. Intensive Care*, 2015, **43**, 341–350.
- 60 N. A. Ahmad, S. M. Awaluddin, R. Samad, N. M. Kasim, M. Yusof, M. A. Abd Razak, C. Y. Ying and N. Sahril, *International Journal of Biomedicine*, 2015, 5, 91–94.
- 61 A. S. Ahankari, A. W. Fogarty, L. J. Tata, J. V. Dixit and P. R. Myles, *BMJ Innov.*, 2016, 2, 70.

- 62 J. Punter-Villagrasa, J. Cid, C. Páez-Avilés, I. Rodríguez-Villarreal, E. Juanola-Feliu, J. Colomer-Farrarons and P. L. Miribel-Català, *Sensors*, 2015, 15, 4564–4577.
- 63 X. Yang, J. Kanter, N. Z. Piety, M. S. Benton, S. M. Vignes and S. S. Shevkoplyas, *Lab Chip*, 2013, 13, 1464–1467.
- 64 C. T. Quinn, M. C. Paniagua, R. K. DiNello, A. Panchal and M. Geisberg, *Br. J. Haematol.*, 2016, 175, 724–732.
- 65 P. T. McGann, B. A. Schaefer, M. Paniagua, T. A. Howard and R. E. Ware, *Am. J. Hematol.*, 2016, **91**, 205–210.
- 66 A. A. Kumar, M. R. Patton, J. W. Hennek, S. Y. Lee, G. D'Alesio-Spina, X. Yang, J. Kanter, S. S. Shevkoplyas, C. Brugnara and G. M. Whitesides, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 14864–14869.
- 67 A. A. Kumar, C. Chunda-Liyoka, J. W. Hennek, H. Mantina, S. Y. R. Lee, M. R. Patton, P. Sambo, S. Sinyangwe, C. Kankasa, C. Chintu, C. Brugnara, T. P. Stossel and G. M. Whitesides, *PLoS One*, 2014, 9, e114540.
- 68 S. M. Knowlton, I. Sencan, Y. Aytar, J. Khoory, M. M. Heeney,
  I. C. Ghiran and S. Tasoglu, *Sci. Rep.*, 2015, 5, 15022.
- 69 J. Kanter, M. J. Telen, C. Hoppe, C. L. Roberts, J. S. Kim and X. Yang, *BMC Med.*, 2015, **13**, 225.

- R. An, Y. Huang, Y. Man, R. W. Valentine, E. Kucukal, U. Goreke, Z. Sekyonda, C. Piccone, A. Owusu-Ansah, S. Ahuja, J. A. Little and U. A. Gurkan, *Lab Chip*, 2021, 21, 1843–1865.
- 71 D. F. Keren, D. Hedstrom, R. Gulbranson, C. N. Ou and R. Bak, Am. J. Clin. Pathol., 2008, 130, 824–831.
- 72 N. Borbely, L. Phelan, R. Szydlo and B. Bain, J. Clin. Pathol., 2013, 66, 29–39.
- 73 M. Nusrat, B. Moiz, A. Nasir and M. Rasool Hashmi, BMC Res. Notes, 2011, 4, 103.
- 74 P. Sharma and R. Das, World J. Methodol., 2016, 6, 20–24.
- 75 Clinical & Laboratory Standards Institute, *Measurement Procedure Comparison and Bias Estimation Using Patient Samples*, 3rd edn, 2018.
- 76 G. Shan, X. Li and W. Huang, Innovation, 2020, 1, 100031.
- 77 H. Marn and J. A. Critchley, *Lancet Glob. Health*, 2016, 4, e251–e265.
- 78 W. A. Arishi, H. A. Alhadrami and M. Zourob, *Micromachines*, 2021, 12, 519.
- 79 A. A. Kumar, M. R. Patton, J. W. Hennek, S. Y. R. Lee, G. D'Alesio-Spina, X. Yang, J. Kanter, S. S. Shevkoplyas, C. Brugnara and G. M. Whitesides, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 14864.